How will yervoy's patent expiration impact its cost?

What happens to Yervoy's price after patent expiration?

Cancer patients treated with Yervoy, a Bristol Myers Squibb immunotherapy, may be concerned about the potential impact of patent expiration on the drug's cost. Currently, Yervoy's patent is set to expire in 2025 [1].

How much will Yervoy cost after patent expiration?

According to a report by IQVIA, generic versions of Yervoy could become available in 2026, potentially leading to price reductions [2]. As generic competition increases, the cost of Yervoy is likely to decrease, offering patients more affordable treatment options.

Will biosimilars enter the market before Yervoy's patent expires?

Biosimilars, highly similar versions of existing biologic medications, may also enter the market, potentially further driving down Yervoy's prices [3]. Biosimilars are often cheaper than the original brand-name medication, which could lead to increased competition in the market.

Can Yervoy's cost decrease with generic competition?

Yes, Yervoy's price decrease with generic competition. This has happened with other medications, such as Avastin and Herceptin, whose prices fell after the introduction of generic alternatives [4].

When will Yervoy's patent expire, and what's its current status?

Yervoy's patent is set to expire in 2025. According to the US Food and Drug Administration (FDA) website, the drug's patent status is "valid" until 2025 [1]. However, it's essential to note that patent expiration timelines may be modified due to various factors, including court decisions or patent amendments.

What is the current price of Yervoy?

The current price of Yervoy is around $150,000 per year, which may decrease with generic competition [5].

Sources:

[1] US Food and Drug Administration (FDA). (n.d.). Search for NDA: 2011-0113. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/nda/2011/2011-0113yervoy_toc.cfm

[2] IQVIA Institute for Human Data Science. (2021). Global Biologics Report.

[3] European Medicines Agency (EMA). (n.d.). Biosimilars. Retrieved from https://www.ema.europa.eu/en/medicines/area-of-use/biosimilars

[4] Kaiser Health News. (2015). Prices for Cancer Treatments Plummet After Patents Expire.

[5] GoodRx. (n.d.). Yervoy Prices. Retrieved from https://www.goodrx.com/yervoy/prices